Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598· Phase 3· Eli Lilly and Company· Source
Contact: Samuel Kareff (principal investigator)
Active, not recruiting
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· Phase 3· Pfizer· Source
Active, not recruiting
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455· Phase 3· NRG Oncology· Source
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
NCT04729959· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NCT05050084· Phase 3· NRG Oncology· Source
Active, not recruiting
A Beta-only IL-2 ImmunoTherapY Study
NCT05086692· Phase 1/2· Medicenna Therapeutics, Inc.· Source
Active, not recruiting
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038· Phase 3· Loxo Oncology, Inc.· Source
Active, not recruiting
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04513717· Phase 3· NRG Oncology· Source
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
NCT04658862· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
National Cancer Institute "Cancer Moonshot Biobank"
NCT04314401· National Cancer Institute (NCI)· Source
Active, not recruiting
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
NCT04155034· Phase 3· SWOG Cancer Research Network· Source
Active, not recruiting
Single Fraction Stereotactic Radiosurgery or Three to Five Fraction Stereotactic Radiosurgery in Treating Patients With Brain Metastasis That Has Been Removed by Surgery
NCT04114981· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
NCT03994796· Phase 2· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
NCT03811002· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
NCT03550391· Phase 3· Canadian Cancer Trials Group· Source
Active, not recruiting
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
NCT03574571· Phase 3· Memorial Sloan Kettering Cancer Center· Source
Active, not recruiting
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
NCT03180268· Phase 3· NRG Oncology· Source
Active, not recruiting
DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
NCT03115333· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
NCT02595944· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
NCT02523014· Phase 2· Alliance for Clinical Trials in Oncology· Source
Contact: Liat N. Dagan (principal investigator)
Active, not recruiting
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
NCT02193282· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT02152982· Phase 2/3· National Cancer Institute (NCI)· Source
Active, not recruiting
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
NCT02179086· Phase 2· NRG Oncology· Source
Active, not recruiting
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
NCT02152631· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738· National Cancer Institute (NCI)· Source
Active, not recruiting
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
NCT01274338· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
NCT01134614· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT00588770· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
NCT00499330· Alliance for Clinical Trials in Oncology· Source